A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Neuroendocrine Neoplasm
Interventions
- DRUG: Lutetium[177Lu] Oxodotreotide Injection
Sponsor
Sinotau Pharmaceutical Group